Overview

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
0
Participant gender:
All
Summary
The primary purpose of this study is to evaluate the efficacy of (SEROQUEL SR™ ) quetiapine fumarate sustained-release (SR) compared to placebo in the treatment of anxiety symptoms in patients with generalized anxiety disorder (GAD). PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Paroxetine
Quetiapine Fumarate
Criteria
Inclusion Criteria:

- Male or female aged 18 to 65 years;

- A diagnosis of generalized anxiety disorder;

- Absence of current episode of major depression.

Exclusion Criteria:

- The presence or history of schizophrenia and other psychotic disorders;

- Hypertension;

- A current diagnosis of cancer, unless in remission for at least 5 years